Immune dysregulation is associated with symptom dimensions and cognitive deficits in schizophrenia: accessible evidence from complete blood count

Table 4 Correlations between CBC and cognitive performance in healthy controls and patients with schizophrenia

	Total MCCB		SCT		HVLT		SST		NAB		BVMT		SF
	HC	SCZ	HC	SCZ	HC	SCZ	HC	SCZ	HC	SCZ	HC	SCZ	HC	SCZ
WBC	< 0.001	0.137	0.892	0.004	0.029	0.029	< 0.001	0.012	0.002	0.214	0.053	0.322	0.045	0.030
Plt	0.210	0.667	0.054	0.404	0.387	0.665	0.645	0.987	0.892	0.886	0.297	0.749	0.280	0.858
Neu	0.001	0.478	0.871	0.137	0.016	0.333	0.003	0.341	0.002	0.378	0.058	0.875	0.093	0.112
Lym	0.123	0.945	0.197	0.548	0.912	0.509	0.154	0.782	0.916	0.526	0.937	0.577	0.489	0.864
Mon	0.955	0.259	0.463	0.010	0.838	0.728	0.972	0.755	0.363	0.502	0.596	0.068	0.467	0.549
NLR	0.132	0.430	0.481	0.163	0.061	0.466	0.211	0.358	0.055	0.162	0.296	0.811	0.441	0.158
PLR	0.039	0.896	0.300	0.504	0.100	0.487	0.010	0.888	0.003	0.467	0.252	0.701	0.577	0.908
MLR	0.527	0.383	0.961	0.028	0.960	0.543	0.364	0.770	0.348	0.969	0.654	0.092	0.333	0.513

Variables such as gender, age, BMI, smoking, marriage, and education level were adjusted in healthy controls. Course of disease and drug equivalent dose. In addition, the schizophrenia patient group was additionally corrected for disease duration and drug equivalent dose

ISSN: 1471-244X